Cerus starts Phase I study of blood system

11/25/2008 | RTT News

Cerus Corp. has commenced a Phase I clinical trial of its INTERCEPT Blood System for red blood cells to evaluate the post-transfusion recovery and lifespan of patients who received transfusions with INTERCEPT-treated red blood cells compared with patients who received transfusions with untreated red blood cells. The trial is expected to conclude in the second quarter of 2009.

View Full Article in:

RTT News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY